US2019071511A1PendingUtilityA1
Immunoglobulin variants and uses thereof
Est. expiryDec 16, 2022(expired)· nominal 20-yr term from priority
Inventors:Camellia W. AdamsAndrew ChanCraig CrowleyHenry B. LowmanGerald R. NakamuraLeonard G. Presta
A61P 9/00A61P 9/10A61P 5/40A61P 37/02A61P 7/04A61P 5/14A61P 43/00A61P 9/14A61P 37/08A61P 7/06A61P 3/10A61P 9/08A61P 37/00A61P 37/06A61P 5/00A61P 27/02A61P 35/00A61P 31/06A61P 27/16A61P 29/00A61P 25/00A61P 31/18A61P 35/02A61P 13/12A61P 11/08A61P 17/00A61P 17/06A61P 1/00A61P 17/02A61P 15/08A61P 1/16A61P 11/00A61P 19/02A61P 1/12A61P 1/04A61P 11/06A61P 21/04A61P 17/14A61P 11/02C07K 2317/72C07K 2317/56C07K 2317/92C07K 16/2887C07K 2317/734A61K 2039/505C12N 15/63C12N 5/16C07K 2317/52C07K 2317/55C07K 2317/732C07K 2317/24C07K 2317/75C07K 2317/565C07K 2317/41A61K 39/39558C07K 2317/73C07K 2317/567C07K 2317/522C07K 16/00C07K 16/28
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
Claims
exact text as granted — not AI-modified1 - 81 . (canceled)
82 : An isolated nucleic acid encoding an antibody that binds to human CD20 or an antigen-binding fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A.
83 : A vector comprising the nucleic acid of claim 82 .
84 : An isolated host cell comprising the nucleic acid of claim 82 .
85 : An isolated host cell comprising the vector of claim 83 .
86 : An isolated host cell comprising a first vector comprising a nucleic acid encoding the heavy chain variable region (VH) of an antibody or antigen-binding fragment thereof, and a second vector comprising a nucleic acid encoding the light chain variable region (VL) of the antibody or antigen-binding fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A; and wherein the antibody binds to human CD20.
87 : A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof, encoded by the nucleic acid present in the host cell of claim 84 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.
88 : A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof, encoded by the nucleic acid in the vector present in the host cell of claim 85 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.
89 : A method of producing an antibody that binds to human CD20 or antigen-binding fragment thereof, comprising culturing a host cell under conditions so that the antibody or antigen-binding fragment is produced, wherein the host cell comprises a first vector and a second vector encoding the antibody or antigen-binding fragment thereof, wherein the first vector comprises a nucleic acid encoding the heavy chain variable region (VH) of the antibody, and the second vector comprises a nucleic acid encoding the light chain variable region (VL) of the antibody, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A.
90 : An isolated nucleic acid encoding an antibody that binds to human CD20 or an antigen-binding fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitutions S26A, S56A and S92A.
91 : A vector comprising the nucleic acid of claim 90 .
92 : An isolated host cell comprising the nucleic acid of claim 90 .
93 : An isolated host cell comprising the vector of claim 91 .
94 : A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof, encoded by the nucleic acid present in the host cell of claim 92 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.
95 : A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof, encoded by the nucleic acid in the vector present in the host cell of claim 93 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.
96 : A method of producing an antibody that binds to human CD20 or antigen-binding fragment thereof, comprising culturing a host cell under conditions so that the antibody or antigen-binding fragment is produced, wherein the host cell comprises a first vector and a second vector encoding the antibody or antigen-binding fragment thereof, wherein the first vector comprises a nucleic acid encoding the heavy chain variable region (VH) of the antibody, and the second vector comprises a nucleic acid encoding the light chain variable region (VL) of the antibody, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitutions S26A, S56A and S92A.Join the waitlist — get patent alerts
Track US2019071511A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.